American Century Companies Inc. Lowers Holdings in Solventum Corporation $SOLV

American Century Companies Inc. reduced its stake in shares of Solventum Corporation (NYSE:SOLV) by 5.5% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 113,101 shares of the company’s stock after selling 6,547 shares during the period. American Century Companies Inc. owned approximately 0.07% of Solventum worth $8,578,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Strengthening Families & Communities LLC grew its holdings in Solventum by 376.8% during the first quarter. Strengthening Families & Communities LLC now owns 329 shares of the company’s stock worth $25,000 after acquiring an additional 260 shares during the period. Barrett & Company Inc. lifted its holdings in Solventum by 206.2% in the second quarter. Barrett & Company Inc. now owns 398 shares of the company’s stock valued at $30,000 after acquiring an additional 268 shares during the period. IMG Wealth Management Inc. purchased a new stake in Solventum in the 2nd quarter worth approximately $31,000. Smartleaf Asset Management LLC grew its stake in shares of Solventum by 193.4% during the 1st quarter. Smartleaf Asset Management LLC now owns 534 shares of the company’s stock worth $40,000 after purchasing an additional 352 shares during the period. Finally, MTM Investment Management LLC acquired a new stake in shares of Solventum during the 2nd quarter worth approximately $40,000.

Solventum Trading Up 0.2%

SOLV stock opened at $85.41 on Friday. The company has a current ratio of 1.50, a quick ratio of 1.14 and a debt-to-equity ratio of 1.03. Solventum Corporation has a 12-month low of $60.70 and a 12-month high of $88.20. The stock has a market cap of $14.81 billion, a price-to-earnings ratio of 9.84, a PEG ratio of 9.00 and a beta of 0.26. The business’s 50-day moving average is $75.10 and its 200 day moving average is $74.06.

Solventum (NYSE:SOLV) last posted its quarterly earnings results on Thursday, November 6th. The company reported $1.50 EPS for the quarter, beating the consensus estimate of $1.43 by $0.07. Solventum had a return on equity of 28.01% and a net margin of 18.13%.The firm had revenue of $2.10 billion during the quarter, compared to analysts’ expectations of $2.05 billion. During the same quarter last year, the firm earned $1.64 earnings per share. The business’s revenue for the quarter was up .7% on a year-over-year basis. Solventum has set its FY 2025 guidance at 5.980-6.080 EPS. On average, sell-side analysts anticipate that Solventum Corporation will post 6.58 EPS for the current fiscal year.

Solventum declared that its board has approved a stock buyback program on Thursday, November 20th that allows the company to repurchase $1.00 billion in shares. This repurchase authorization allows the company to reacquire up to 7.5% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company’s leadership believes its stock is undervalued.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the stock. Jefferies Financial Group assumed coverage on shares of Solventum in a research note on Thursday, September 11th. They issued a “hold” rating and a $80.00 target price for the company. BTIG Research upgraded shares of Solventum from a “neutral” rating to a “buy” rating and set a $100.00 price objective for the company in a research report on Tuesday. UBS Group reissued a “neutral” rating on shares of Solventum in a research note on Friday, November 21st. Wells Fargo & Company lifted their price target on Solventum from $79.00 to $82.00 and gave the company an “equal weight” rating in a research note on Monday, September 15th. Finally, Piper Sandler upped their price target on Solventum from $94.00 to $98.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. Four investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $87.00.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.